TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Variations of serum C reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient-reported symptoms as measured by ESAS-r
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fraction of exhaled Nitric Oxide (FeNO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Signs and Symptoms of Ocular Surface Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Drinks Per Drinking Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days Abstinent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number Initiating Alcohol Use Disorder Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Echocardiogram marker measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: One-year local tumor progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change of serum sodium after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chronic GVHD-free, Relapse-free Survival Probability
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients requiring transfusion of packed red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of ADRs regarding Bone marrow depression, ILD, new primary malignancies, Embryo-foetal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of ADRs not expected from Precautions for Use of LYNPARZA JPI
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clot Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clot Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of death from all causes
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of recurrent pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hemodynamic deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual Encounter Profile Question 3
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in albumin/creatinine ratio (ACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in renal plasma flow (RPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in glomerular permeability (GP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Feasibility of treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Deaths related to toxin spread
Endpoint domain: Mortality/survival
Primary endpoint: Change in 10 Meter Walk Test (10MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged duration prescribing rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants With Any Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the level of difficulty in self-care
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in the level of difficulty in baby-care
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Postpartum depression
Endpoint domain: Adverse events/effects
Primary endpoint: Postpartum quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in OSA severity defined by Apnoea-Hypopnoea Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dementia Rating Scale (DRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Wound Area Mean Percent Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to active labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change from baseline Mediterranean Diet Score at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Disease Activity Score (DAS28) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Health Assessment Questionnaire (HAQ) Score at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adynamic ileus resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety profile of ORCA-010
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline Short Form Health Survey 12-items (SF-12) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in functional balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and severity of local tolerability issues at the injection site
Endpoint domain: Adverse events/effects
Primary endpoint: Number and severity of hypoglycaemic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Postprandial lipid measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MCA PI change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incretin change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in indices of insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in pancreatic steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correctly identified basal cell carcinoma and subtype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Subjects Reporting Fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent epithelial defect healing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients achieving mRS 0-3
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidental discovery of malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in ankle circumference for joint swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement of Symptoms and Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: At Least 50% Shrinkage in Tumor Measurements by Physical Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response by MRI Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of EN41-UGR7C administrations
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of EN41-UGR7C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ELISPOT assay results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bioavailability of desmopressine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of RLS symptoms (IRLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in WPAI
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in trabeculae bone score (TBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: local anesthetic consumption reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high on-treatment platelet reactivity (HPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in the Timed Up and Go Test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fasting triglyceride concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection rate of Barrett's associated high grade esophageal dysplasia and esophageal adenocarcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Root mean squared difference in Respiratory Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Residual Volume Variation from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Functional Residual Capacity variation from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of RTOG/CTC Grade ≥ 2 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Cross sectional area (CSA) on Magnetic Resonance Imaging knee scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decay times from Magnetic Resonance Imaging knee scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patellar tendon biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Erectile Function Domain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Treatment Persistence Duration Measured for Index Medication (Tofacitinib)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean Adherence To Methotrexate (MTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Claims Based Index of RA Severity (CIRAS) Score During Pre-Index Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cranial diffusion tractography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Fugl-Meyer Assessment Scale score (FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New-onset Cardiovascular Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: New-onset Fragility Fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fall Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Scores on Working memory and attentional control
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After ACTH-challenge at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Albumin-corrected Serum Calcium From Baseline to Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Analgesics consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rating Scale for Psychogenic Movement Disorders (RSPMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Grade 3 or Greater Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Cessation of bleeding after 30 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graded-scale of improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Parathyroid Hormone (PTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Dose-Normalized AUC[0-Inf]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-Normalized AUC[0-24]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-Normalized Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of gefitinib
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of late toxicities associated with gefitinib and standard cranial radiation
Endpoint domain: Adverse events/effects
Primary endpoint: Variability of intraocular pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: HAM-D 32 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specific anti-HBV vaccine response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean change in the Raynaud's Condition Score (RCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving clear or almost clear on Physician Global Assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of preovulatory follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Participants Who Develop Vacuolization in the Inner Nuclear Layer (INL) of the Retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to Reach Maximum Observed Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gastroesophageal reflux occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: IL-32 isoforms levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Influenza seroprotection post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acoustic startle magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax, AUC, tmax of rabeprazole and its major metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal scars on DMSA renal scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety and tolerability of RBT-1
Endpoint domain: Adverse events/effects
Primary endpoint: Subject compliance with PCR
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change in penile curvature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in PDQ responses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean time for skin grafting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean of hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: mean of pain for patients of age <8 years assessed by Visual Analogue Score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: mean of pain for patients of age >8 years assessed by Face, Leg, Activity, Cry, Consolabilty Pain Scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: AUC0-2h of plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: △Cmax of plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Maximum Absolute Change in Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Maximum Percent Change in Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Histologically-confirmed Cervical Intraepithelial Neoplasia (CIN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of HPV 6/11/16/18-related Cervical Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of HPV-related Histologically Confirmed Female Genital Diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Blood Cholecystokinin (CCK) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gallbladder (GB) Wall Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gallbladder (GB) Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gallbladder (GB) Ejection Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of surgical wound appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clearance of P falciparum parasites from the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Instrumental delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Survival post initial recurrence or progression
Endpoint domain: Mortality/survival
Primary endpoint: 10 centimeter Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Tampa Scale of Kinesiophobia (TSK)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Modified Oswestry Disability Index (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tissue eosinophilia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: quadriceps performance recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Variation of MRA grading of large vessel vasculitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of PET Vascular Activity Score (PETVAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with relapse-free remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Maximum log10 HCV RNA Following Multiple Dose Oral Administration of MK-1075
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in sitting diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: stimulation frequency effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic quality of [18F]ISO-1-PET/CT images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Internalizing outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Externalizing outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: School outcomes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Immunoglobulin IgG dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall Response (Complete and Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocaine Use Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Desensitized Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival for each tumor type
Endpoint domain: Mortality/survival
Primary endpoint: Western Ontario Shoulder Instability (WOSI) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: best corrected visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Knowledge about smoking
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Game experience satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline arterial blood gases analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline haemostasis analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Do not require ICD implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Continue WCD use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Meet GDMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Parent Fidelity of PRT Implementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti SARS-CoV-2 S IgG antibody response(ELISA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutralizing antibody response to SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Time From Admission to Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach the Target Hb Range in Correction Group Only
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number and type of referred patients with psychosocial problems
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Treatment - Emergent Adverse Events
Endpoint domain: Adverse events/effects